Gufic Bioscience Told To Submit More Data for Piperacillin-Tazobactam-Sodium Chloride FDC

Written By :  Dr. Divya Colin
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-06-15 04:00 GMT   |   Update On 2025-06-15 04:00 GMT
Advertisement

New Delhi: In response to the proposal presented by Gufic Bioscience, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined that firm to submit more scientific literature available from peer reviewed journal in support of the proposed fixed dose combination (FDC) Piperacillin plus Tazobactam pluss Sodium Chloride.

This came after the firm presented their proposal along with justification for BE & Phase III CT waiver before the committee.

Advertisement

Piperacillin is a broad-spectrum antibiotic used to treat various bacterial infections, often combined with tazobactam to enhance its effectiveness against bacteria that produce beta-lactamase enzymes.

Tazobactam is a beta-lactamase inhibitor used in combination with the antibiotic piperacillin to treat bacterial infections. It works by preventing bacteria from destroying piperacillin, allowing the antibiotic to effectively kill the bacteria.

Sodium chloride, also known as salt, common salt, table salt or halite, is an ionic compound with the chemical formula NaCl, representing a 1:1 ratio of sodium and chloride ions. Sodium chloride is the primary salt in seawater and in the extracellular fluid of many multicellular organisms

At the recent SEC meeting for Antimicrobial and Antiviral held on 14th May 2025, the expert panel reviewed the proposal along with justification for BE & Phase III CT waiver before the committee.

After detailed deliberation, the committee opined the following:

1. The strength of diluent i.e. Sodium chloride injection 0.9%w/v is different from similar USFDA approved product.

2. The firm should present more scientific literature available from peer reviewed journal in support of the proposed FDC with Sodium chloride injection 0.9%w/v.

Accordingly, the firm should submit the above justification for further review by the committee.

Also Read: Intas Gets CDSCO Panel Nod to Conduct Phase III Trial of Pertuzumab Biosimilar for Breast Cancer


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News